Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS)

BACKGROUND Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in young children and older adults. A long-acting anti-RSV monoclonal antibody (nirsevimab) and bivalent pre-fusion F-protein pregnancy vaccine became available to prevent RSV in young children in 2024; two RS...

ver descrição completa

Detalhes bibliográficos

Autor principal:	FluCAN-PAEDS network
Formato:	Artigo
Idioma:	Inglês
Publicado em:	European Centre for Disease Prevention and Control 2026-01-01
coleção:	Eurosurveillance
Assuntos:	Australia nirsevimab vaccine effectiveness immunisation respiratory syncytial virus acute respiratory infection
Acesso em linha:	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2026.31.2.2500275
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!